GlassScriptPhysician profile
Arthur B Vegh
NPI 1144210048
$27,621.89
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $2,135 · 2021: $2,518 · 2022: $284.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $10,134.24 | 2019-2021 | |
| Csl Behring | $5,744.41 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $5,702.86 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $4,633.34 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $381.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $328.24 | 2019-2022 | |
| Octapharma USA, INC. | $253.27 | 2019-2021 | |
| Shire North American Group INC | $174.02 | 2019 | |
| Genzyme Corporation | $52.50 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.90 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.11 | 2020-2021 | |
| Circassia INC. | $28.47 | 2019 | |
| Kaleo, INC. | $25.49 | 2019-2021 | |
| Pfizer INC. | $21.35 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.03 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $17.30 | 2022 | |
| Grifols USA, LLC | $11.64 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Vegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.